Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | EZH2 | Q15910 | 10/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939209 | 0.91 | ALDH1A1 (0.43) | MEN1ALDH1A1KMT2APDE3BPDE3A | |
| SCHEMBL1336948 | 0.90 | AKR1B1 (0.38) | SMN1; SMN2EZH2 | |
| SCHEMBL4492829 | 0.87 | AKR1B1 (0.35) | SMN1; SMN2EZH2 | |
| SCHEMBL6032269 | 0.83 | P2RX7 (0.37) | ALDH1A1LMNAHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL4486283 | 0.83 | P2RX7 (0.37) | ALDH1A1LMNAHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL1335829 | 0.80 | MEN1 (0.37) | MEN1ALDH1A1KMT2ALMNAHTT | |
| SCHEMBL3023303 | 0.79 | EZH2 (0.32) | EZH2 | |
| SCHEMBL1336823 | 0.79 | EZH2 (0.32) | EZH2 | |
| SCHEMBL4478189 | 0.79 | LMNA (0.46) | MEN1ALDH1A1KMT2APDE3BPDE3A | |
| SCHEMBL1336853 | 0.78 | P2RX7 (0.42) | MEN1ALDH1A1KMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598264-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | disclosed |
| EP-1725556-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005087768-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179196-A1 | Hiv integrase inhibitors | REV1, TYMP, POLR2H | MEN1 4754/4885ALDH1A1 1500/4885KMT2A 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.